The recent decision by the U.S. Food and Drug Administration (FDA) not to approve a critical treatment for a life-threatening pediatric illness is a heavy blow to families in need. It’s disappointing, to say the least. Many compassionate Americans might react to this news with disbelief. This stance not only seems morally wrong but also politically inconsistent.
Bureaucrats shouldn’t let political agendas overshadow potentially life-saving options that families of terminally ill children are willing to take risks for.
This month, some Democrats noted that limiting the enrollment period for the Affordable Care Act could lead to more lives lost.
Political motivations at play
Yet, it’s striking that one of their own could be responsible for actual lives lost. Dr. Vinai Prasad, notable for his affiliation with Bernie Sanders, leads the FDA—and despite treatments having cleared the approval process under the previous administration, the FDA declined two life-saving treatments for children with rare conditions.
Dr. Prasad identifies as a “lifelong progressive Democrat” and serves as the Director of the FDA’s Center for Oncology and Biologics. He’s certainly qualified, especially given his extensive research experience in oncology. Still, his refusal to allow the COVID-19 vaccine for those over 12 raises questions regarding his judgment on patient care.
But this isn’t just about ideology. His actions seem to deny terminally ill children a chance at life.
Children cannot afford to wait
Dr. Prasad recently dismissed two potential treatments for serious pediatric illnesses, specifically Duchenne muscular dystrophy and Sanfilippo syndrome.
A child with Duchenne typically has a life expectancy of only 22 years, with the condition gradually deteriorating their muscles and neurological functions.
Sanfilippo syndrome, often described as “childhood Alzheimer’s,” is equally devastating; most affected children don’t survive beyond their early teens.
Consider a little girl battling Sanfilippo syndrome. Her website, “Save Sadie Rae,” reveals the bright spirit her family cherishes. However, she’s in a fight for her life, and her parents are advocating fervently for a reversal of the FDA’s decision, emphasizing that it sends a troubling message: “We don’t care about your child.”
The FDA has postponed its final decision until next year, but families like Sadie’s know that delays can be deadly. Time is not on their side.
Parents of children with these kinds of illnesses aren’t your typical lobbyists or medical professionals. They are everyday individuals facing unimaginable challenges and searching desperately for hope. They are pleading for the FDA to take meaningful steps forward.
Bureaucratic hurdles kill
Recently, in discussions with Peter Pitts, a former FDA advisory committee member involved with the Duchenne community, he expressed frustration with the agency’s current stance.
In recent years, the FDA has been notably more receptive to the voices of parents whose children suffer from rare and devastating conditions. This shift allows parents to consider higher risks for treatments that may offer new hope, without completely disregarding the principles of regulatory science.
Pitts continued:
The parents in this community are clearly demonstrating a willingness to accept greater risks for the sake of their children’s well-being. It raises the question: Does Dr. Prasad’s aversion towards the pharmaceutical industry—often mirrored in Democrats’ talking points—dismiss the needs of children battling conditions like Duchenne or Sanfilippo?
While the developers of Sanfilippo treatments claim a strong track record of effectiveness, the FDA has focused instead on manufacturing concerns that seem distant from the immediate needs of patients.
Is this a genuine issue, or simply a justification for inaction?
Related discussions highlight the bureaucratic obstacles enforced by political agendas that hinder real progress in treatment access.
Moreover, when the FDA rejected Duchenne cell therapy, it claimed the biotechnology companies did not present “substantial evidence of effectiveness,” ignoring that children and young adults are facing dire circumstances without these treatments.
Advancements in technology, bioengineering, and gene therapy represent hope for countless families grappling with orphan diseases.
Fighting for a chance
If parents of terminally ill children are willing to embrace significant risks under Trump’s “right to try” initiative—or other FDA-approved avenues—then political uncertainties should not impede life-saving decisions. They hope these treatments could aid their kids, understanding that such efforts might primarily benefit future generations.
This selfless perspective ought to be considered by the FDA as it navigates these crucial choices.
Families facing fatal conditions have issued a clarion call to the FDA. It’s possible that, with fresh leadership in the medical office, the FDA might heed this urgent appeal and act on behalf of children who can’t advocate for themselves.
